Natpara Approved for Hypoparathyroidism
The U.S. Food and Drug Administration (FDA) approval of Natpara (parathyroid hormone) in addition to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Natpara is manufactured by NPS Pharmaceuticals.
The recommended dose of Natpara starts at 50mcg once a day and it is a self-administered subcutaneous injection into the thigh. The dose should be individualized to achieve a serum calcium level in the lower half of the normal range. NPS Pharmaceuticals plans on launching Natpara in the second quarter of 2015 through a limited network of specialty pharmacies.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.